1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1725-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LINONG JI und 15 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Zovaglutide, a once-monthly GLP-1 receptor agonist, has shown clinically meaningful weight loss with a favorable safety profile in participants with overweight or obesity in 24 weeks in a phase 2 study. This analysis was to explore the glucose-lowering effect of zovaglutide in prediabetes subgroup.
Methods
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study was conducted in adults with overweight (24 kg/m2≤BMI<28 kg/m2) with at least one co-morbidity or obesity (BMI≥28 kg/m2) but without diabetes. Participants were randomized (3:3:2:2:2) to receive zovaglutide 80 mg or 160 mg once every 4 weeks (Q4W), zovaglutide 80 mg or 160 mg once every 2 weeks (Q2W), or matched placebo for 24 weeks. The prediabetes subgroup was defined as participants with HbA1c≥5.7% at baseline and with available HbA1c value at week 24. The primary outcome was the proportion of participants who transitioned to an HbA1c level<5.7% (below the diagnostic threshold for prediabetes) at week 24.
Results
Among the 303 participants randomized, 116 participants met the definition of prediabetes subgroup. The subgroup baseline characteristics were generally balanced across all treatment groups, of which 48.3% were female, mean age was 33.4 years, mean BMI was 35.3 kg/m2 and mean HbA1c was 5.9%. The proportions of participants achieved HbA1c<5.7% at week 24 in zovaglutide 80 mg Q4W group, 160 mg Q4W group, 80 mg Q2W group and 160 mg Q2W group were greater than in placebo group (93.5%, 96.4%, 90.5% and 100.0% vs. 22.2%). The percentage changes from baseline in weight in zovaglutide groups at week 24 were significantly greater than in placebo group (-10.8%, -12.8%, -12.9% and -12.8% vs. -0.8%, all p values<0.0001). The most common adverse events were gastrointestinal and mostly were mild to moderate in severity. No adverse events led to treatment discontinuation.
Conclusion
Once-monthly zovaglutide normalized glucose levels in participants with prediabetes and overweight or obesity over 24 weeks. Disclosure L. Ji: None. L. Gao: None. X. Zou: None. J. Zhang: None. H. Jiang: Consultant; Current; Innovent Biologics. Z. Cheng: None. D. Liu: None. J. Tian: None. K. Wang: None. H. Shu: None. X. Dong: None. L. Liu: None. X. Song: None. R. Zhao: None. X. Zhang: None. Y. Zhang: None.
Zitieren
APA
JI, L., GAO, L., ZOU, X., ZHANG, J., JIANG, H., CHENG, Z., LIU, D. X., TIAN, J., WANG, K., SHU, H. Y., DONG, X., LIU, L., SONG, X., ZHAO, R., ZHANG, X., & ZHANG, Y. (2026). 1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1725-p
Vancouver
JI L, GAO L, ZOU X, ZHANG J, JIANG H, CHENG Z, et al. 1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1725-p
BibTeX
@article{JI2026,
author = {JI, LINONG and GAO, LEILI and ZOU, XIANTONG and ZHANG, JUNQING and JIANG, HONGWEI and CHENG, ZHIFENG and LIU, DE XUE and TIAN, JUNHANG and WANG, KUN and SHU, HONG YAN and DONG, XIAOLIN and LIU, LI and SONG, XIAOYING and ZHAO, RUIHUA and ZHANG, XUJIA and ZHANG, YUANYUAN},
title = {1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1725-p}
}
EUVIMED